What is HC Wainwright’s Forecast for Annexon Q1 Earnings?

Annexon, Inc. (NASDAQ:ANNX) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Annexon in a research report issued on Tuesday, March 4th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.33) for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.28) EPS.

A number of other research analysts have also weighed in on ANNX. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Annexon Stock Performance

Shares of ANNX stock opened at $2.76 on Friday. The stock’s fifty day moving average is $3.75 and its two-hundred day moving average is $5.34. The firm has a market capitalization of $294.20 million, a P/E ratio of -2.63 and a beta of 1.14. Annexon has a fifty-two week low of $2.30 and a fifty-two week high of $8.40.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Parkman Healthcare Partners LLC raised its holdings in shares of Annexon by 0.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock worth $1,945,000 after acquiring an additional 1,768 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Annexon by 1.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after acquiring an additional 2,450 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Annexon by 10.7% during the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after acquiring an additional 3,355 shares during the period. E Fund Management Co. Ltd. raised its holdings in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Annexon by 6.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after acquiring an additional 4,092 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.